Detalhe da pesquisa
1.
Characterizing Cellular Responses During Oncolytic Maraba Virus Infection.
Int J Mol Sci
; 20(3)2019 Jan 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-30700020
2.
Spatial and temporal epithelial ovarian cancer cell heterogeneity impacts Maraba virus oncolytic potential.
BMC Cancer
; 17(1): 594, 2017 Aug 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-28854921
3.
Vesiculovirus neutralization by natural IgM and complement.
J Virol
; 88(11): 6148-57, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24648451
4.
Maraba virus as a potent oncolytic vaccine vector.
Mol Ther
; 22(2): 420-429, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24322333
5.
Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.
Mol Ther
; 22(7): 1320-1332, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-24695102
6.
Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
Mol Ther
; 21(11): 2043-53, 2013 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-23985699
7.
Oncolytic Vaccinia virus safely and effectively treats skin tumors in mouse models of xeroderma pigmentosum.
Int J Cancer
; 132(3): 726-31, 2013 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22733395
8.
Harnessing oncolytic virus-mediated antitumor immunity in an infected cell vaccine.
Mol Ther
; 20(9): 1791-9, 2012 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-22760544
9.
Getting oncolytic virus therapies off the ground.
Cancer Cell
; 4(1): 7-11, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12892708
10.
VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents.
Cancer Cell
; 4(4): 263-75, 2003 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-14585354
11.
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancer.
Front Immunol
; 13: 1029269, 2022.
Artigo
em Inglês
| MEDLINE | ID: mdl-36405739
12.
Identification of genetically modified Maraba virus as an oncolytic rhabdovirus.
Mol Ther
; 18(8): 1440-9, 2010 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-20551913
13.
Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis.
Proc Natl Acad Sci U S A
; 105(39): 14981-6, 2008 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-18815361
14.
Deletion of immunomodulatory genes as a novel approach to oncolytic vaccinia virus development.
Mol Ther Oncolytics
; 22: 85-97, 2021 Sep 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-34514091
15.
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.
Clin Cancer Res
; 15(8): 2777-88, 2009 Apr 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19351762
16.
Vesicular stomatitis virus oncolysis of T lymphocytes requires cell cycle entry and translation initiation.
J Virol
; 82(12): 5735-49, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18417567
17.
Virus therapy for cancer.
Sci Am
; 311(5): 54-9, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25464663
18.
Codelivery of mRNA with α-Galactosylceramide Using a New Lipopolyplex Formulation Induces a Strong Antitumor Response upon Intravenous Administration.
ACS Omega
; 4(8): 13015-13026, 2019 Aug 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-31460428
19.
Type I IFN blockade uncouples immunotherapy-induced antitumor immunity and autoimmune toxicity.
J Clin Invest
; 129(2): 518-530, 2019 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30422820
20.
Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials.
Oncoimmunology
; 8(1): e1512329, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-30546947